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OBJECTIVES: The advantages of improved adherence to
immunosuppression include reduced morbidity, mortality, and
health care costs. Our aim was to examine calcineurin inhibitor
(CNI) adherence following kidney transplantation and the effect
on hospital days and health care costs. METHODS: US claims
data from 10 US health plans for de novo patients receiving
kidney transplants between 1995 and 2005 were employed.
Patients with ≥ one post-transplant claim for cyclosporine mod-
iﬁed (CsA) or tacrolimus (tac) were included. CNI adherence was
deﬁned as the medication possession ratio (MPR) or the number
of therapy days supplied to the number of followup days during
the year following the ﬁrst CNI claim. Patients who switched to
another CNI medication or were not continuously enrolled in
the health plan were excluded. Zero-inﬂated negative binomial
regression was used to examine the relationship between CNI
adherence and hospital days. RESULTS: Of 821 enrolled
patients, 51% were in the CsA and 49% in the tac cohorts. The
groups were not different with regard to age, gender, income,
level of comorbidity, or number of hospital days during the
adherence measurement period. A total of 28% of the CsA group
was 100% adherent (MPR = 1) compared to 21% in the tac
group (p = 0.02). Holding patient characteristics and prior uti-
lization constant, receiving CsA was associated with 15 (95%
CI: 5, 40) fewer hospital days compared to tac. Also, increasing
levels of adherence by one standard deviation reduced days spent
in the hospital by 12 (95% CI: 9, 30). This difference in hospi-
tal days likely impacted total health care costs, which were sig-
niﬁcantly lower for CsA ($13,949) compared to tac ($20,896)
during the same period (p = 0.009). CONCLUSIONS: Receiv-
ing cyclosporine modiﬁed following transplantation was associ-
ated with higher levels of adherence, fewer hospitalizations, and
lower total health care costs.
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OBJECTIVES: To estimate the amount of government health
budget required for the extension of access to renal replacement
therapy (RRT) towards beneﬁciaries of the universal health care
coverage (UC) scheme in Thailand. Ability of the government to
bear the increasing budget and appropriate measures to cope
with anticipated costs of including RRT in the beneﬁt package
were also investigated. METHODS: Literature review on
demand for RRT at both domestic and international levels, and
the estimate of costs for haemodialysis and continuous peritoneal
dialysis in Thailand. From the government perspective, several
scenarios of budget requirements according to the estimated
costs for RRT and possible rationing criteria were calculated.
RESULTS: The government would spend approximately more
than ﬁve billion Baht during the ﬁrst year of implementation, if
there is neither strategy to reduce the costs for RRT nor appro-
priate selection criteria for end-stage renal disease patients. The
budget for universal access to RRT would increase to 74,355
million Baht in the sixteenth year of implementation if the gov-
ernment played passive roles in controlling costs of the program.
The budget required would reduce to 58% of the estimate if the
government introduced the rationing criteria for patients aged
less than 60 years. CONCLUSIONS: The policy on the exten-
sion of access to RRT should be considered carefully by the gov-
ernment because of its ﬁnancial impact on the government health
budget. Appropriate interventions including effective measures
to control costs of RRT, strategies to reduce the incidence of end-
stage renal disease, and the rationing criteria for access to RRT
are needed if the decision to implement the policy is made.
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OBJECTIVES: Despite concerns regarding bioequivalence of
NB-CsA to B-CsA, generics constitute the second most widely
used form of CsA in the US. We assessed whether potential cost
savings associated with the lower acquisition cost of generics are
realized with NB-CsA. METHODS: Claims data from eight
commercial health plans were linked to Organ Procurement
Transplant Network data. De novo kidney recipients with ≥1
pharmacy claim for B-CsA (n = 247) or NB-CsA (n = 64) were
included. Information was collected for 1 year before and after
initial (index) CsA claim. Patients who switched between study
drugs or had <1 year pre- or post-index data were excluded. Log
transform regression with backward selection was used to model
costs in the ﬁrst year post-index. Statistical signiﬁcance of cohort
differences in predicted costs was determined by bootstrapping
with 1000 repetitions. RESULTS: Baseline demographics were
similar between the two cohorts; 62% male, 60% age >45 years,
and 10% African American. Total prescription medication costs
were higher for NB vs. B-CsA ($14,233 vs. $12,606, p = 0.04),
reﬂecting higher costs for both immunosuppressant (IS) and non-
IS drugs incurred by the NB-CsA cohort. NB-CsA patients had
higher inpatient costs ($17,459 vs. $7904), more hospitalizations
(4.5 vs. 3.2, respectively), and slightly higher outpatient costs
($8547 vs. $7477) vs. B-CsA. Utilization for gastrointestinal
symptoms (e.g., abdominal pain, vomiting, diarrhea) was higher
in the NB vs. B-CsA cohort (13% vs. 5%, p = 0.04) as were total
health care costs ($40,239 vs. $27,988, p = 0.07). After con-
trolling for patient characteristics and pre-transplant costs, total
costs were 27% higher (p = 0.03) for NB vs. B-CsA. For the
average patient taking NB vs. B-CsA, predicted costs were $8291
higher (95% CI: $122, $21,278). CONCLUSIONS: Despite
lower acquisition cost of generics, de novo renal transplant recip-
ients initiated on NB-CsA incurred increased health care costs,
which appeared to be driven by costly pharmacy and inpatient
utilization.
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